Skip to main content

Advertisement

SpringerLink
Log in

Real-world effectiveness and rheumatologist satisfaction with secukinumab in the treatment of patients with axial spondyloarthritis

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Objectives

To assess the effectiveness of secukinumab in patients with axSpA treated in routine clinical settings in 5 European countries.

Methods

Retrospective analysis of a cross-sectional survey to assess real-world effectiveness of secukinumab in the management of axSpA and rheumatologist satisfaction with treatment in France, Germany, Italy, Spain and the UK from March to December 2018. Outcomes collected included patient demographics, clinical characteristics and rheumatologist- and patient-reported satisfaction with secukinumab treatment.

Results

Five hundred thirty-five patients receiving secukinumab for more than 4 months were assessed, 359 of whom were diagnosed with AS and 178 with nr-axSpA. Rheumatologist assessment of disease status at treatment initiation indicated that 39 (7.3%) had stable/improving disease. Secukinumab treatment for 4 months or longer resulted in 515 (95.9%) patients judged as stable/improving. Treatment was associated with benefits from initiation to assessment in terms of BASDAI (6.2 vs 2.8), 44-joint count score (9.7 vs 6.6), rheumatologist global VAS score (56.9 vs 23.0) and patient global VAS scores (64.4 vs 25.5). These benefits for key clinical outcomes were sustained for periods of 12 months or longer. Patient-reported outcomes on health status using EQ-5D, global functioning using the ASAS health index and overall work impairment via WPAI were sustained over the treatment period, while patient and rheumatologist satisfaction with secukinumab treatment remained very high at 80.2 and 91.2%, respectively.

Conclusion

Consistent benefits across multiple clinical and patient-reported outcomes were seen with secukinumab treatment in patients with AS and nr-axSpA treated in routine clinical settings across five European countries.

Key Points

• In routine clinical settings across five European countries, secukinumab treatment resulted in improvements in a wide range of clinical outcomes including physician-reported disease severity, disease status, pain, BASDAI, 44-joint count score and global VAS scores.

• Key clinical and patient reported outcomes were sustained for a 12-month period or longer with secukinumab treatment.

• Rheumatologist- and patient-reported treatment satisfaction was high with secukinumab.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data availability

The data that support the findings of this study are available from Adelphi Real World, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of Adelphi Real World.

References

  1. Sieper J, Poddubnyy D (2017) Axial spondyloarthritis. Lancet (London, England) 390(10089):73–84. https://doi.org/10.1016/s0140-6736(16)31591-4

    Article  Google Scholar 

  2. Sieper J, Braun J, Dougados M, Baeten D (2015) Axial spondyloarthritis. Nature reviews Disease primers 1:15013. https://doi.org/10.1038/nrdp.2015.13

  3. Rudwaleit M, Khan MA, Sieper J (2005) The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum 52(4):1000–1008. https://doi.org/10.1002/art.20990

    Article  PubMed  Google Scholar 

  4. Mease PJ, Heijde DV, Karki C, Palmer JB, Liu M, Pandurengan R, Park Y, Greenberg JD (2018) Characterization of patients with ankylosing spondylitis and nonradiographic axial spondyloarthritis in the US-Based Corrona Registry. Arthritis Care Res 70(11):1661–1670. https://doi.org/10.1002/acr.23534

    Article  Google Scholar 

  5. Deodhar A, Mease PJ, Reveille JD, Curtis JR, Chen S, Malhotra K, Pangan AL (2016) Frequency of axial spondyloarthritis diagnosis among patients seen by US rheumatologists for evaluation of chronic back pain. Arthritis & rheumatology (Hoboken, NJ) 68(7):1669–1676. https://doi.org/10.1002/art.39612

    Article  CAS  Google Scholar 

  6. Poddubnyy D (2013) Axial spondyloarthritis: is there a treatment of choice? Therapeutic advances in musculoskeletal disease 5(1):45-54. https://doi.org/10.1177/1759720X12468658

  7. van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud H, Dougados M, van Gaalen F, Géher P, van der Horst-Bruinsma I, Inman RD, Jongkees M, Kiltz U, Kvien TK, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compàn V, Ozgocmen S, Pimentel-Santos FM, Reveille J, Rudwaleit M, Sieper J, Sampaio-Barros P, Wiek D, Braun J (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76(6):978–991. https://doi.org/10.1136/annrheumdis-2016-210770

    Article  PubMed  Google Scholar 

  8. Davis JC, Jr., Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W, Enbrel Ankylosing Spondylitis Study G (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48(11):3230–3236. https://doi.org/10.1002/art.11325

    Article  CAS  Google Scholar 

  9. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study G (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52(2):582–591. https://doi.org/10.1002/art.20852

    Article  CAS  Google Scholar 

  10. van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, Dijkmans BA, Mease PJ, Davis JC, Jr., Group AS (2009) Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Annals of the rheumatic diseases 68 (6):922-929. https://doi.org/10.1136/ard.2007.087270

  11. Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A, Fang MA, Louie G, Majithia V, Ng B, Bigham R, Pianin M, Shah AA, Sullivan N, Turgunbaev M, Oristaglio J, Turner A, Maksymowych WP, Caplan L (2019) 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis & rheumatology (Hoboken, NJ) 71(10):1599–1613. https://doi.org/10.1002/art.41042

    Article  Google Scholar 

  12. Brahe CH, Ørnbjerg LM, Askling J, Ciurea A, Kristianslund EK, Onen F, Nordström D, Santos MJ CC, Rotar Z, Gudbjornsson B, Di Giuseppe D, Nissen MJ, Kvien T, Birlik M, Trokovic N, Barcelos A, Ionescu R, Tomšič M, Geirsson AJ, Loft AG, Mann HF, Rusman T, Gomez-Reino JJ, Jones GT, Iannone F, Pavelka K, van der Horst-Bruinsma I, Hyldstrup L, Krogh NS, Hetland ML, Østergaard M. (2018) Drug retention and response rates of TNFi treatment in 21,470 patients with axial spondyloarthritis treated in clinical practice– pooled data from the Eurospa Research Network Collaboration. Arthritis & rheumatology (Hoboken, NJ) 70 (suppl 10).

  13. McGonagle DG, McInnes IB, Kirkham BW, Sherlock J, Moots R (2019) The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann Rheum Dis 78(9):1167–1178. https://doi.org/10.1136/annrheumdis-2019-215356

    Article  CAS  PubMed  Google Scholar 

  14. Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB, Group MS, Group MS (2015) Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 373(26):2534–2548. https://doi.org/10.1056/NEJMoa1505066

    Article  CAS  Google Scholar 

  15. Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P, Readie A, Martin R, Mpofu S, Richards HB, group Ms, (2017) Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis 76(6):1070–1077. https://doi.org/10.1136/annrheumdis-2016-209730

    Article  CAS  PubMed  Google Scholar 

  16. Deodhar A, Conaghan PG, Kvien TK, Strand V, Sherif B, Porter B, Jugl SM, Gandhi KK, group Ms, (2019) Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study. Clin Exp Rheumatol 37(2):260–269

    PubMed  Google Scholar 

  17. Marzo-Ortega H, Sieper J, Kivitz AJ, Blanco R, Cohen M, Pavelka K, Delicha EM, Stefanska A, Richards HB, Rohrer S (2020) 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial. Lancet Rheumatol 2(6):e339–e346. https://doi.org/10.1016/S2665-9913(20)30066-7

    Article  Google Scholar 

  18. Baraliakos X, Braun J, Deodhar A, Poddubnyy D, Kivitz A, Tahir H, Van den Bosch F, Delicha EM, Talloczy Z, Fierlinger A (2019) Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open 5(2):e001005. https://doi.org/10.1136/rmdopen-2019-001005

    Article  PubMed  PubMed Central  Google Scholar 

  19. Braun J, Blanco R, Dokoupilova E, Gensler LS, Kivitz A, Hall S, Kameda H, Poddubnyy D, Van de Sande M, Van der Heijde D, Wiksten A, Porter B, Richards H, Haemmerle S, Deodhar A (2020) OP0106 Secukinumab 150 mg significantly improved signs and symptoms of non-radiographic axial spondyloarthritis: 52-week results from the phase iii PREVENT study. Ann Rheum Dis 79(1):69–70. https://doi.org/10.1136/annrheumdis-2020-eular.598

    Article  Google Scholar 

  20. Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, Leonardi C, Porter B, Das Gupta A, Widmer A, Pricop L, Fox T (2019) Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther 21(1):111. https://doi.org/10.1186/s13075-019-1882-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Anderson P, Benford M, Harris N, Karavali M, Piercy J (2008) Real-world physician and patient behaviour across countries: disease-specific programmes - a means to understand. Curr Med Res Opin 24(11):3063–3072. https://doi.org/10.1185/03007990802457040

    Article  CAS  PubMed  Google Scholar 

  22. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286–2291

    CAS  PubMed  Google Scholar 

  23. van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, van Rijswijk MH, van de Putte LB (1990) Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Annals of the rheumatic diseases 49 (11):916-920. https://doi.org/10.1136/ard.49.11.916

  24. Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35(11):1095–1108. https://doi.org/10.1097/00005650-199711000-00002

    Article  CAS  PubMed  Google Scholar 

  25. EuroQol G (1990) EuroQol–a new facility for the measurement of health-related quality of life. Health Policy 16(3):199–208. https://doi.org/10.1016/0168-8510(90)90421-9

    Article  Google Scholar 

  26. Kiltz U, van der Heijde D, Boonen A, Cieza A, Stucki G, Khan MA, Maksymowych WP, Marzo-Ortega H, Reveille J, Stebbings S, Bostan C, Braun J (2015) Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. Ann Rheum Dis 74(5):830–835. https://doi.org/10.1136/annrheumdis-2013-203967

    Article  CAS  PubMed  Google Scholar 

  27. Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4(5):353–365. https://doi.org/10.2165/00019053-199304050-00006

    Article  CAS  PubMed  Google Scholar 

  28. Public Policy Committee ISoP (2016) Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf 25(1):2–10. https://doi.org/10.1002/pds.3891

    Article  Google Scholar 

  29. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M, initiative S, (2007) Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med 147(8):W163-194. https://doi.org/10.7326/0003-4819-147-8-200710160-00010-w1

    Article  PubMed  Google Scholar 

  30. Ariza-Ariza R, Hernandez-Cruz B, Lopez-Antequera G, Navarro-Sarabia F (2009) Variables related to utility in patients with ankylosing spondylitis. Clin Rheumatol 28(2):207–211. https://doi.org/10.1007/s10067-008-1019-5

    Article  PubMed  Google Scholar 

  31. Elolemy G, Aboughanima A, Ganeb S, Elziat H (2020) Health-related quality of life in patients with ankylosing spondylitis: relationship with disease-related variables. Curr Rheumatol Rev 16(4):311–318. https://doi.org/10.2174/1573397115666191018162606

    Article  CAS  PubMed  Google Scholar 

  32. Kiltz U, Peterlik D, Winkelmann V, Tony H-P (2019) FRI0406 AQUILA study in Germany - Real world data on secukinumab’s effectiveness in ankylosing spondylitis patients - results from an interim analysis. Ann Rheum Dis 78(Suppl 2):890–890. https://doi.org/10.1136/annrheumdis-2019-eular.437

    Article  Google Scholar 

  33. Michelsen B, Brahe CH, Askling J, Codreanu C, Ciurea A, Loft AG, Mann H, Pombo-Suarez M, Onen F, Sexton J, Rotar Z, Santos MJ, Eklund K, Gudbjornsson B, Iannone F, Giuseppe DD, Ionescu R, Nissen M, Pavelka K, Sánchez-Piedra C, Akar S, Kristianslund E, Tomsic M, Santos H, Trokovic N, Geirsson AJ, Favalli EG, Ivd H-B, Macfarlane G, Hyldstrup L, Krogh NS, Ǿstergaard M, Hetland ML (2019) FRI0404 Pooled 6-month treatment outcomes and drug retention rates in 1556 patients with axial spondyloarthritis treated with secukinumab in routine clinical practice in 12 European countries in the EUROSPA research collaboration. Ann Rheum Dis 78(Suppl 2):888–889. https://doi.org/10.1136/annrheumdis-2019-eular.1601

    Article  Google Scholar 

  34. Chen Q, Beal EW, Okunrintemi V, Cerier E, Paredes A, Sun S, Olsen G, Pawlik TM (2019) The association between patient satisfaction and patient-reported health outcomes. J Patient Exp 6(3):201–209. https://doi.org/10.1177/2374373518795414

    Article  PubMed  Google Scholar 

  35. Kaye DR, Richardson CR, Ye Z, Herrel LA, Ellimoottil C, Miller DC (2017) Association between patient satisfaction and short-term outcomes after major cancer surgery. Ann Surg Oncol 24(12):3486–3493. https://doi.org/10.1245/s10434-017-6049-2

    Article  PubMed  PubMed Central  Google Scholar 

  36. Derakhshan MH, Pathak H, Cook D, Dickinson S, Siebert S, Gaffney K, Nass, investigators BR, (2018) Services for spondyloarthritis: a survey of patients and rheumatologists. Rheumatology (Oxford) 57(6):987–996. https://doi.org/10.1093/rheumatology/kex518

    Article  Google Scholar 

  37. Magrey M, Bozyczko M, Wolin D, Mordin M, McLeod L, Davenport E, Chirila C, Park Y (2019) A pilot study to assess the feasibility of a web-based survey to examine patient-reported symptoms and satisfaction in patients with ankylosing spondylitis receiving secukinumab. Drugs Real World Outcomes 6(2):83–91. https://doi.org/10.1007/s40801-019-0154-4

    Article  PubMed  PubMed Central  Google Scholar 

  38. Gonzalez CM, Carmona L, de Toro J, Batlle-Gualda E, Torralba AI, Arteaga MJ, Cea-Calvo L (2017) Perceptions of patients with rheumatic diseases on the impact on daily life and satisfaction with their medications: RHEU-LIFE, a survey to patients treated with subcutaneous biological products. Patient Prefer Adherence 11:1243–1252. https://doi.org/10.2147/PPA.S137052

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Dr Conaghan is supported in part through the UK NIHR Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

Funding

This study was funded by Novartis. Adelphi received funding from Novartis to conduct this research.

Author information

Authors and Affiliations

  1. Rheumazentrum Ruhrgebiet, Herne, Germany

    U. Kiltz

  2. Ruhr Universität, Bochum, Germany

    U. Kiltz

  3. Novartis Pharma AG, Basel, Switzerland

    D. L. Keininger

  4. Adelphi Real World, Bollington, UK

    E. A. Holdsworth, N. Booth & O. Howell

  5. Novartis Healthcare Pvt Ltd, Hyderabad, India

    N. Modi

  6. Novartis Pharmaceuticals Corporation, East Hanover, USA

    H. Tian

  7. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, UK

    P. G. Conaghan

Authors
  1. U. Kiltz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. L. Keininger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. A. Holdsworth
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. Booth
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. O. Howell
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N. Modi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H. Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. P. G. Conaghan
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors had full access to the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. All authors were involved in (1) conception or design or analysis and interpretation of data; (2) drafting and revising the article; (3) providing intellectual content of critical importance to the work described; and (4) final approval of the version to be published and therefore meet the criteria for authorship in accordance with the International Committee of Medical Journal Editors (ICMJE) guidelines. In addition, all named authors take responsibility for the integrity of the work as a whole and have given their approval for this version to be published.

Medical writing assistance was provided by David Whitford, who provided paid consultancy services/editorial support to Adelphi/Novartis in the present study.

Corresponding author

Correspondence to U. Kiltz.

Ethics declarations

Conflicts of interest/competing interests

Dr. Kiltz has received grant and research support and consultancy fees from AbbVie, Amgen, Biocad, Biogen, Chugai, Eli Lilly, Fresenius, Gilead, Grünenthal, GSK, Janssen, MSD, Novartis, Pfizer, Roche and UCB. Dr Conaghan has served as a consultant or on speaker’s bureaus for AbbVie, BMS, Eli Lilly, Galapagos, Gilead, GSK, Novartis, and Pfizer. Dorothy Keininger, Niraj Modi and Haijun Tian are employees of Novartis. Elizabeth Holdsworth, Nicola Booth and Oliver Howell are employees of Adelphi Real World.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kiltz, U., Keininger, D.L., Holdsworth, E.A. et al. Real-world effectiveness and rheumatologist satisfaction with secukinumab in the treatment of patients with axial spondyloarthritis. Clin Rheumatol 41, 471–481 (2022). https://doi.org/10.1007/s10067-021-05957-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-021-05957-4

Keywords

Search

Navigation